IDEXX Laboratories, Inc. $IDXX Shares Acquired by Diversified Trust Co.

Diversified Trust Co. lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 223.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,199 shares of the company’s stock after buying an additional 2,901 shares during the quarter. Diversified Trust Co.’s holdings in IDEXX Laboratories were worth $2,841,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. Empowered Funds LLC lifted its holdings in IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after acquiring an additional 95 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth approximately $265,000. TD Waterhouse Canada Inc. grew its stake in shares of IDEXX Laboratories by 249.6% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 430 shares of the company’s stock worth $233,000 after purchasing an additional 307 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of IDEXX Laboratories by 22.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 543,582 shares of the company’s stock valued at $291,555,000 after purchasing an additional 100,517 shares in the last quarter. Finally, MAI Capital Management increased its holdings in shares of IDEXX Laboratories by 22.6% during the 2nd quarter. MAI Capital Management now owns 1,065 shares of the company’s stock valued at $571,000 after purchasing an additional 196 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Michael G. Erickson sold 5,371 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the transaction, the executive vice president owned 12,693 shares in the company, valued at approximately $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Nimrata Hunt sold 2,693 shares of the business’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total value of $1,781,527.22. Following the transaction, the executive vice president directly owned 19,899 shares in the company, valued at $13,163,984.46. This trade represents a 11.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 45,957 shares of company stock worth $29,862,109. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $570.21 on Wednesday. The firm has a 50-day simple moving average of $639.93 and a 200-day simple moving average of $663.76. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $45.34 billion, a price-to-earnings ratio of 43.63, a price-to-earnings-growth ratio of 3.51 and a beta of 1.66. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Barclays lowered their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Piper Sandler cut their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Finally, UBS Group dropped their target price on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $783.33.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.